Cargando…
Targeting Inflammation Driven by HMGB1
High mobility group box 1 (HMGB1) is a highly conserved, nuclear protein present in all cell types. It is a multi-facet protein exerting functions both inside and outside of cells. Extracellular HMGB1 has been extensively studied for its prototypical alarmin functions activating innate immunity, aft...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7099994/ https://www.ncbi.nlm.nih.gov/pubmed/32265930 http://dx.doi.org/10.3389/fimmu.2020.00484 |
_version_ | 1783511398536445952 |
---|---|
author | Yang, Huan Wang, Haichao Andersson, Ulf |
author_facet | Yang, Huan Wang, Haichao Andersson, Ulf |
author_sort | Yang, Huan |
collection | PubMed |
description | High mobility group box 1 (HMGB1) is a highly conserved, nuclear protein present in all cell types. It is a multi-facet protein exerting functions both inside and outside of cells. Extracellular HMGB1 has been extensively studied for its prototypical alarmin functions activating innate immunity, after being actively released from cells or passively released upon cell death. TLR4 and RAGE operate as the main HMGB1 receptors. Disulfide HMGB1 activates the TLR4 complex by binding to MD-2. The binding site is separate from that of LPS and it is now feasible to specifically interrupt HMGB1/TLR4 activation without compromising protective LPS/TLR4-dependent functions. Another important therapeutic strategy is established on the administration of HMGB1 antagonists precluding RAGE-mediated endocytosis of HMGB1 and HMGB1-bound molecules capable of activating intracellular cognate receptors. Here we summarize the role of HMGB1 in inflammation, with a focus on recent findings on its mission as a damage-associated molecular pattern molecule and as a therapeutic target in inflammatory diseases. Recently generated HMGB1-specific inhibitors for treatment of inflammatory conditions are discussed. |
format | Online Article Text |
id | pubmed-7099994 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-70999942020-04-07 Targeting Inflammation Driven by HMGB1 Yang, Huan Wang, Haichao Andersson, Ulf Front Immunol Immunology High mobility group box 1 (HMGB1) is a highly conserved, nuclear protein present in all cell types. It is a multi-facet protein exerting functions both inside and outside of cells. Extracellular HMGB1 has been extensively studied for its prototypical alarmin functions activating innate immunity, after being actively released from cells or passively released upon cell death. TLR4 and RAGE operate as the main HMGB1 receptors. Disulfide HMGB1 activates the TLR4 complex by binding to MD-2. The binding site is separate from that of LPS and it is now feasible to specifically interrupt HMGB1/TLR4 activation without compromising protective LPS/TLR4-dependent functions. Another important therapeutic strategy is established on the administration of HMGB1 antagonists precluding RAGE-mediated endocytosis of HMGB1 and HMGB1-bound molecules capable of activating intracellular cognate receptors. Here we summarize the role of HMGB1 in inflammation, with a focus on recent findings on its mission as a damage-associated molecular pattern molecule and as a therapeutic target in inflammatory diseases. Recently generated HMGB1-specific inhibitors for treatment of inflammatory conditions are discussed. Frontiers Media S.A. 2020-03-20 /pmc/articles/PMC7099994/ /pubmed/32265930 http://dx.doi.org/10.3389/fimmu.2020.00484 Text en Copyright © 2020 Yang, Wang and Andersson. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Yang, Huan Wang, Haichao Andersson, Ulf Targeting Inflammation Driven by HMGB1 |
title | Targeting Inflammation Driven by HMGB1 |
title_full | Targeting Inflammation Driven by HMGB1 |
title_fullStr | Targeting Inflammation Driven by HMGB1 |
title_full_unstemmed | Targeting Inflammation Driven by HMGB1 |
title_short | Targeting Inflammation Driven by HMGB1 |
title_sort | targeting inflammation driven by hmgb1 |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7099994/ https://www.ncbi.nlm.nih.gov/pubmed/32265930 http://dx.doi.org/10.3389/fimmu.2020.00484 |
work_keys_str_mv | AT yanghuan targetinginflammationdrivenbyhmgb1 AT wanghaichao targetinginflammationdrivenbyhmgb1 AT anderssonulf targetinginflammationdrivenbyhmgb1 |